Coastlands Capital (NASDAQ: ADIL) buys 3,233 ADIAL shares in open market

Rhea-AI Filing Summary

Coastlands Capital LP, a 10% owner of ADIAL Pharmaceuticals, reported two open‑market purchases of common stock. It bought 2,000 shares at $2.65 on July 14, 2026 and 1,233 shares at $2.75 on July 16, 2026. Following these trades, Coastlands reported 388,308 shares of ADIL common stock held indirectly, and the related entities disclaim beneficial ownership except to the extent of their pecuniary interests.

Insider Trade Summary

Net Buyer: 3,233 shares ($8,691)

Net Buy 2 txns

Insider Coastlands Capital LP

Role 10% Owner

Bought 3,233 shs ($9K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,233	$2.75	$3K
Purchase	Common Stock	2,000	$2.65	$5K

Holdings After Transaction: Common Stock — 388,308 shares (Indirect, By Coastlands Capital LP)

Footnotes (1)

1. [object Object]

Key Figures

Shares purchased 2026-07-16: 1,233 shares Shares purchased 2026-07-14: 2,000 shares Total shares purchased: 3,233 shares +3 more

6 metrics

Shares purchased 2026-07-16 1,233 shares Open-market purchase of ADIL common stock at $2.75 per share on July 16, 2026

Shares purchased 2026-07-14 2,000 shares Open-market purchase of ADIL common stock at $2.65 per share on July 14, 2026

Total shares purchased 3,233 shares Total ADIL common shares bought in the reported July 2026 transactions

Purchase price 2026-07-16 $2.75 per share Price paid for ADIL common stock on July 16, 2026

Purchase price 2026-07-14 $2.65 per share Price paid for ADIL common stock on July 14, 2026

Holdings after transactions 388,308 shares Indirect ADIL common stock holdings reported after the July 16, 2026 trade

Key Terms

open-market purchase, ten percent owner, indirect ownership, pecuniary interest, +1 more

5 terms

open-market purchase financial

"Transaction code P is described as a purchase in open market or private transaction"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

ten percent owner financial

"Coastlands Capital LP is identified as a ten percent owner of the issuer"

indirect ownership financial

"Ownership type is coded as indirect with nature of ownership "By Coastlands Capital LP""

pecuniary interest financial

"Each reporting person disclaims beneficial ownership except to the extent of that person's pecuniary interest"

beneficial ownership financial

"Each reporting person also disclaims beneficial ownership of common stock"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/16/2026 - 05:09 PM Accepted by SEC EDGAR 07/16/2026 - 05:08 PM Learn about SEC filing dates

FAQ

What insider transaction did Coastlands Capital LP report for ADIL?

Coastlands Capital LP reported open-market purchases of ADIAL Pharmaceuticals common stock. It bought 3,233 shares across two trades in July 2026, increasing its indirectly held position while associated entities disclaim beneficial ownership beyond their pecuniary interest.

How many ADIL shares did Coastlands Capital LP buy and at what prices?

Coastlands Capital LP bought 2,000 ADIL shares at $2.65 on July 14, 2026 and 1,233 shares at $2.75 on July 16, 2026. In total, the Form 4 reports 3,233 shares acquired in open-market transactions.

What are Coastlands Capital LP's ADIL holdings after these Form 4 trades?

After the July 16, 2026 purchase, Coastlands Capital LP reported 388,308 ADIL common shares held indirectly. The ownership is coded as indirect, with the nature of ownership noted as "By Coastlands Capital LP" and beneficial ownership disclaimed except for pecuniary interest.

Is Coastlands Capital LP a ten percent owner of ADIAL Pharmaceuticals (ADIL)?

Yes, Coastlands Capital LP is identified as a ten percent owner of ADIAL Pharmaceuticals. This status means its reported holdings are significant relative to the company, and its trades must be disclosed on Form 4 under insider reporting rules.

Were there any ADIL share sales reported by Coastlands Capital LP in this Form 4?

No. The Form 4 for Coastlands Capital LP shows only open-market purchases of ADIL common stock, with no reported sales. Transaction code "P" is used for both entries, indicating purchase in open market or private transactions.

Who controls Coastlands Capital LP in relation to these ADIL transactions?

The footnote states that Matthew Perry is the control person of Coastlands, its general partners, and the related partnership. Each reporting person, however, disclaims beneficial ownership of the common stock beyond his or its pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coastlands Capital LP

(Last) (First) (Middle)

601 CALIFORNIA STREET

SUITE 1210

(Street)

SAN FRANCISCO CALIFORNIA 94108

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ADIAL PHARMACEUTICALS, INC. [ ADIL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/14/2026		P		2,000	A	$2.65	387,075	I	By Coastlands Capital LP(1)
Common Stock	07/16/2026		P		1,233	A	$2.75	388,308	I	By Coastlands Capital LP(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein.

	/s/ Mark Shamia, Chief Operating Officer of the General Partner of Coastlands Capital LP	07/16/2026
	/s/ Mark Shamia, Chief Operating Officer of the General Partner of Coastlands Capital Partners LP	07/16/2026
	/s/ Mark Shamia, Chief Operating Officer of Coastlands Capital GP LLC	07/16/2026
	/s/ Mark Shamia, Chief Operating Officer of Coastlands Capital LLC	07/16/2026
	/s/ Matthew D. Perry	07/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)